Why is Sun Pharma Advanced Research Company Ltd ?
- NET SALES(Latest six months) At Rs 1,861.67 cr has Grown at 4,322.02%
- PAT(Latest six months) Higher at Rs 1,693.28 cr
- OPERATING PROFIT TO INTEREST(Q) The company hardly has any interest cost
- Institutional investors have increased their stake by 1.43% over the previous quarter and collectively hold 4% of the company
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors
- The stock has generated a return of 45.64% in the last 1 year, much higher than market (BSE500) returns of 4.11%
How much should you buy?
- Overall Portfolio exposure to SPARC should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is SPARC for you?
High Risk, High Return
Quality key factors
Valuation Key Factors 
Technical key factors
Technical Movement
At Rs 1,853.22 cr has Grown at 13849.7% (vs previous 4Q average
The company hardly has any interest cost
Highest at Rs 1,773.20 cr.
Highest at 95.68%
Highest at Rs 1,759.16 cr.
Highest at Rs 1,761.34 cr.
Highest at Rs 54.28
Highest at Rs 11.64 cr
Here's what is working for SPARC
Net Sales (Rs Cr)
PBT less Other Income (Rs Cr)
PAT (Rs Cr)
Net Sales (Rs Cr)
Operating Profit (Rs Cr)
Operating Profit to Sales
PBT less Other Income (Rs Cr)
PAT (Rs Cr)
EPS (Rs)
Here's what is not working for SPARC
Interest Paid (Rs cr)
Interest Paid (Rs cr)






